Alpha interferon treatment in myasthenia gravis: Effects on natural killer cell activity

Abbott, 1986, False positive anti-acetylcholine receptor antibodies in motor neuron disease, Lancet, 1, 906, 10.1016/S0140-6736(86)91005-6 Abruzzo, 1983, Homeostasis of the antibody response: Immunoregulation by NK cells, Science, 222, 581, 10.1126/science.6685343 Anlar, 1995, Acetylcholine receptor antibodies and single fibre EMG in first degree relatives of children with myasthenia gravis, Neuropediatrics, 26, 335, 10.1055/s-2007-979788 Aoki, 1985, Attempts to implicate viruses in myasthenia gravis, Neurology, 35, 1381, 10.1212/WNL.35.2.185 Arai, 1983, Suppressive effect of human natural killer cells on pokeweed mitogen-induced B-cell differentiation, J. Immunol., 131, 651, 10.4049/jimmunol.131.2.651 Aybay, 1995, The effect of omeprazole on human natural killer activity, Gen. Pharmacol., 26, 1413, 10.1016/0306-3623(94)00301-3 Batocchi, 1995, Myasthenia gravis during interferon alfa therapy, Neurology, 45, 382, 10.1212/WNL.45.2.382 Biron, 1989, Severe herpes virus infections in a adolescent without natural killer cells, N. Eng. J. Med., 320, 1731, 10.1056/NEJM198906293202605 Boyum, 1976, Isolation of lymphocytes, granulocytes and macrophages, Scand. J. Immunol., 5 (Suppl.), 9, 10.1111/j.1365-3083.1976.tb03851.x Bukowski, 1985, Adoptive transfer studies demontrating the antiviral effect of natural killer cells in vivo, J. Exp. Med., 161, 40, 10.1084/jem.161.1.40 Burn, 1991, A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid dehydrogenase antibodies, J. Neurol. Neurosurg. Psychiatr., 54, 449, 10.1136/jnnp.54.5.449 Cavda, 1988, Inhibition of human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides, Cell Immunol., 115, 57, 10.1016/0008-8749(88)90161-X Cern, 1994, Immunological aspects of HCV infection, Intervirology, 37, 119, 10.1159/000150366 Cueva, 1985, Administration of interferon suppresses clinical and electromyographic signs of MG experimentally transmitted from man to rats, C. R. Acad. Sci. III, 301, 125 Garcia-Penarrubia, P., 1992. Natural killer cells in bacterial infection. In: Lewis, C.E., McGee, J.O. (Eds.), The Natural Killer Cell. Oxford University Press, New York, pp. 67–105. Kott, 1990, Interferon system and natural killer cell activity in myasthenia gravis, Quart. J. Med., 281, 951 Lefvert, 1987, Antibodies against the acetylcholine receptor in hematologic disorders: Implications for the development of myasthenia gravis after bone marrow grafting, N. Eng. J. Med., 317, 170, 10.1056/NEJM198707163170314 Lewis, J.A., 1992. Effects of interferons on mitochondria: Regulation of mitochondrial gene expression. In: Susman M. (Ed.), Interferon: Principles and Medical Applications. The University of Texas Medical Branch at Galveston, TX, pp. 251–260. Mantegazza, 1988, Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis, J. Neurol., 235, 449, 10.1007/BF00314245 Mase, 1996, Development of myasthenia gravis during interferon-α treatment for anti-HCV positive chronic hepatitis, J. Neurol. Neurosurg. Psychiatr., 60, 348, 10.1136/jnnp.60.3.348-a Masters, 1977, Penicillamine associated myasthenia gravis, anti-acetylcholine receptor and anti-striatal antibodies, Am. J. Med., 63, 689, 10.1016/0002-9343(77)90153-X Miller, 1982, Immune regulation in myasthenia gravis: Evidence for an increased suppressor T-cell population, Ann. Neurol., 12, 341, 10.1002/ana.410120405 Morio, 1989, Suppression of in vitro immunglobulin synthesis by CD16(leu11a)+CD56(NHK1 leu19)+non T cell lineage NK cells: Lack of suppression of cells from immundeficient patients, Clin. Exp. Immunol., 78, 159 O'Shea, J., Ortaldo, J.R., 1992. The biology of natural killer cells: Insights into the molecular basis of function. In: Lewis, C.E., McGee, J.O. (Eds.), The Natural Killer Cell. Oxford University Press, New York, pp. 1–40. Osserman, K.L., 1958. Clinical aspects. In: Myasthenia gravis. Grunex Stratton, New York, pp. 66–89. Qu, 1992, A preliminary observation on auto-cholinergic synapse dysfunction in patients with different types of epilepsy, Jpn. J. Psychiatr. Neurol., 46, 401 Perez, 1995, Myasthenia gravis induced by alpha interferon therapy, Am. J. Hematol., 49, 365, 10.1002/ajh.2830490432 Piccolo, 1996, Myasthenia gravis in a patient with chronic active hepatitis C during interferon-α treatment, J. Neurol. Neurosurg. Psychiatr., 60, 348, 10.1136/jnnp.60.3.348 Rauch, 1985, Natural killer cell activity in multiple sclerosis and myasthenia gravis, Immunol. Invest., 14, 427, 10.3109/08820138509047611 Reiter, 1993, Interferon-A: Major regulator of natural killer cell mediated cytotoxicity, J. Interferon Res., 13, 247, 10.1089/jir.1993.13.247 Robertson, 1990, Biology and clinical relevance of human natural killer cells, Blood, 76, 2421, 10.1182/blood.V76.12.2421.2421 Rönnblom, 1991, Autoimmunity after alpha interferon therapy for malignant carcinoid tumors, Ann. Internal. Med., 15, 178, 10.7326/0003-4819-115-3-178 Roos, 1984, Interferon induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells, Cancer Res., 44, 2358 Schattner, 1984, Natural killer cells and the pathogenesis of systemic lupus erythematosus, Arthitis Rheum., 27, 1072, 10.1002/art.1780270924 Schattner, 1990, Virus induced autoimmunity, Rev. Infect. Dis., 12, 204, 10.1093/clinids/12.2.204 Schrier, 1986, Suppression of NK cell activity and T cell proliferation by fresh isolates of human CMV, J. Infect. Dis., 153, 1084, 10.1093/infdis/153.6.1084 Shenoy, 1995, IFNA treatment suppresses the development of experimental autoimmune myasthenia gravis, J. Immunol., 154, 6203, 10.4049/jimmunol.154.11.6203 Whiteside, 1989, The role of natural killer cells in human disease, Clin. Immunol. Immunopathol., 53, 1, 10.1016/0090-1229(89)90096-2